Dynamic cardiac changes in low cardiovascular risk patients with triple negative breast cancer treated with chemo-immunotherapy

Dynamic cardiac changes in low cardiovascular risk patients with triple negative breast cancer treated with chemo-immunotherapy

Abstract Background Neoadjuvant chemotherapy-immunotherapy is the new standard of care for high-risk early-stage triple negative breast cancer (TNBC). As anthracyclines, pembrolizumab, and radiotherapy may each contribute to an increased risk of cardiovascular events, real-world assessment of early...

Full description

Saved in:
Bibliographic Details
Main Authors: Jean Philippe Nesseler, Katrina D. Silos, Olivia Peony, Asneh Singh, Patrick Belen, Mitchell R. Kamrava, Julie K. Jang, Stephen L. Shiao, Alan C. Kwan, Cody Ramin, Raymond H. Mak, Andriana P. Nikolova, Katelyn M. Atkins
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Cardio-Oncology
Subjects:
Cardiac events
Pembrolizumab
Radiation therapy
Triple negative breast cancer
Online Access:https://doi.org/10.1186/s40959-025-00361-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40959-025-00361-2

Similar Items